Combination treatment of bacterial infection
AssigneeThe Chinese University of Hong Kong
InventorsMargaret Ip, Kwok Pui Fung, Ping Chung Leung, Clara Bik San Lau, Quan Bin Han, Chung Lap Chan, Chit Tsui, Quande Wang
Life of this patent
Estimating the term…
Abstract
The present invention resides in the discovery that combined use of kuraridin (or any one of its analogs) and epicatechin gallate (ECG) can provide heightened level of antimicrobial activity, especially for the suppression of bacteria of the Staphylococcus aureus and Staphylococcal species. Compositions, kits, and methods for the combination use are disclosed.
Claims20
A method for suppressing growth of methicillin-resistant Staphylococcus aureus (MRSA), comprising contacting the MRSA with kuraridin in a concentration of about 1-4 μg/ml and epicatechin gallate (ECG) in a concentration of about 0.25-8 μg/ml, optionally further with an antibiotic in an effective amount.
A composition for suppressing MRSA growth, comprising kuraridin in a concentration of about 1-4 μg/ml and epicatechin gallate (ECG) in a concentration of about 0.25-8 μg/ml, optionally further comprising an antibiotic in an effective amount.
A kit for suppressing MRSA growth, comprising (1) a first composition comprising epicatechin gallate (ECG) in a concentration of about 0.25-8 μg/ml;
- and (2) a second composition comprising kuraridin in a concentration of about 1-4 μg/ml.
Dependencies are inferred from the claim text.